Advances in understanding the structure, function, and mechanism of the SCIN and Efb families of staphylococcal immune evasion proteins

Advances in Experimental Medicine and Biology

Volumn 946, Issue , 2012, Pages 113-133

  Garcia, Brandon L ^b   Ramyar, Kasra X ^b   Ricklin, Daniel ^b   Lambris, John D ^b   Geisbrecht, Brian V ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b NONE

Author keywords

C3 Convertase; Complement Inhibitors; Efb; Immune Evasion; Mechanism; SCIN; Staphylococcus aureus; Structural Biology

Indexed keywords

BACTERIAL PROTEIN; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3C; COMPLEMENT COMPONENT C3D; COMPLEMENT INHIBITOR; EFB PROTEIN; SCIN A PROTEIN; SCIN PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; COMPLEMENT SYSTEM; HOST; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN STRUCTURE; STAPHYLOCOCCUS;

BACTERIAL PROTEINS; COMPLEMENT C3B INACTIVATOR PROTEINS; COMPLEMENT INACTIVATOR PROTEINS; HUMANS; IMMUNITY, INNATE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP;

BACTERIA (MICROORGANISMS); STAPHYLOCOCCUS AUREUS;

EID: 80555149778     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0106-3_7     Document Type: Article

References (62)

1. Alsenz, J., Becherer, J.D., Nilsson, B., and Lambris, J.D.1989) Structural and functional analysis of C3 using monoclonal antibodies. Curr. Top. Microbiol. Immunol. 153, 235-248.
2. Becherer, J.D., Alsenz, J., Esparza, I., Hack, C.E., and Lambris, J.D.1992) A segment spanning residues 727-768 of the complement C3 sequence contains a neoantigenic site and accommodates the binding of CR1, factor H, and factor B. Biochemistry 31, 1787-1794.
3. Boden, M.K. and Flock, J.-I.1992) Evidence for three different fibrinogen-binding proteins with unique properties from Staphylococcus aureus strain Newman. Microb. Pathog. 12, 289-298.
4. Carroll, M.C.2004) The complement system in regulation of adaptive immunity. Nat. Immunol. 5, 981-986.
5. Chambers, H.F. and Deleo, F.R.2009) Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 7, 629-641.
6. Chavakis, T., Preissner, K.T. and Herrmann, M.2007) The anti-inflammatory activities of Staphylococcus aureus. Trends Immunol. 28, 408-418.
7. Chen, H., Ricklin, D., Hammel, M., Garcia, B.L., McWhorter, W.J., Sfyroera, G., Wu, Y.Q., Tzekou, A., Li, S., Geisbrecht, B.V., Woods, V.L., Jr. and Lambris, J.D.2010) Allosteric inhibition of complement function by a staphylococcal immune evasion protein. Proc. Natl. Acad. Sci. U. S. A. 107, 17621-17626.
8. Clemenza, L. and Isenman, D.E.2000) Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).J. Immunol. 165, 3839-3848.
9. Deleo, F.R., Otto, M., Kreiswirth, B.N. and Chambers, H.F.2010) Community-associated meticillin- resistant Staphylococcus aureus. Lancet 375, 1557-1568.
10. Forneris, F., Ricklin, D., Wu, J., Tzekou, A., Wallace, R.S., Lambris, J.D. and Gros, P.2010) Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science 330, 1816-1820.
11. Foster, T.J.2005) Immune evasion by Staphylococci. Nat. Rev. Microbiol. 3, 948-958.
12. Frank, M.M.2001) Annihilating host defense. Nat. Med. 7, 1285-1286.
13. Garcia, B.L., Ramyar, K.X., Tzekou, A., Ricklin, D., McWhorter, W.J., Lambris, J.D. and Geisbrecht, B.V.2010) Molecular basis for complement recognition and inhibition determined by crystallographic studies of the staphylococcal complement inhibitor (SCIN) bound to C3c and C3b J. Mol. Biol. 402, 17-29.
14. Geisbrecht, B.V.2008) Staphylococcal complement inhibitors: biological functions, recognition of complement components, and potential therapeutic implications. Adv. Exp. Med. Biol. 632, 221-236.
15. Gorwitz, R.J., Kruszon-Moran, D., McAllister, S.K., McQuillan, G., McDougal, L.K., Fosheim, G.E., Jensen, B.J., Killgore, G., Tenover, F.C. and Kuehnert, M.J.2008) Changes in the
16. preva-Alsenz, J., Becherer, J.D., Nilsson, B., and Lambris, J.D.1989) Structural and functional analysis of C3 using monoclonal antibodies. Curr. Top. Microbiol. Immunol. 153, 235-248.
17. Becherer, J.D., Alsenz, J., Esparza, I., Hack, C.E., and Lambris, J.D.1992) A segment spanning residues 727-768 of the complement C3 sequence contains a neoantigenic site and accommodates the binding of CR1, factor H, and factor B. Biochemistry 31, 1787-1794.
18. Boden, M.K. and Flock, J.-I.1992) Evidence for three different fibrinogen-binding proteins with unique properties from Staphylococcus aureus strain Newman. Microb. Pathog. 12, 289-298.
19. Carroll, M.C.2004) The complement system in regulation of adaptive immunity. Nat. Immunol. 5, 981-986.
20. Chambers, H.F. and Deleo, F.R.2009) Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 7, 629-641.
21. Chavakis, T., Preissner, K.T. and Herrmann, M.2007) The anti-inflammatory activities of Staphylococcus aureus. Trends Immunol. 28, 408-418.
22. Chen, H., Ricklin, D., Hammel, M., Garcia, B.L., McWhorter, W.J., Sfyroera, G., Wu, Y.Q., Tzekou, A., Li, S., Geisbrecht, B.V., Woods, V.L., Jr. and Lambris, J.D.2010) Allosteric inhibition of complement function by a staphylococcal immune evasion protein. Proc. Natl. Acad. Sci. U. S. A. 107, 17621-17626.
23. Clemenza, L. and Isenman, D.E.2000) Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).J. Immunol. 165, 3839-3848.
24. Deleo, F.R., Otto, M., Kreiswirth, B.N. and Chambers, H.F.2010) Community-associated meticillin- resistant Staphylococcus aureus. Lancet 375, 1557-1568.
25. Forneris, F., Ricklin, D., Wu, J., Tzekou, A., Wallace, R.S., Lambris, J.D. and Gros, P.2010) Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science 330, 1816-1820.
26. Foster, T.J.2005) Immune evasion by Staphylococci. Nat. Rev. Microbiol. 3, 948-958.
27. Frank, M.M.2001) Annihilating host defense. Nat. Med. 7, 1285-1286.
28. Garcia, B.L., Ramyar, K.X., Tzekou, A., Ricklin, D., McWhorter, W.J., Lambris, J.D. and Geisbrecht, B.V.2010) Molecular basis for complement recognition and inhibition determined by crystallographic studies of the staphylococcal complement inhibitor (SCIN) bound to C3c and C3b J. Mol. Biol. 402, 17-29.
29. Geisbrecht, B.V.2008) Staphylococcal complement inhibitors: biological functions, recognition of complement components, and potential therapeutic implications. Adv. Exp. Med. Biol. 632, 221-236.
30. Gorwitz, R.J., Kruszon-Moran, D., McAllister, S.K., McQuillan, G., McDougal, L.K., Fosheim, G.E., Jensen, B.J., Killgore, G., Tenover, F.C. and Kuehnert, M.J.2008) Changes
31. preva-Kluytmans, J. and Struelens, M.2009) Meticillin resistant Staphylococcus aureus in the hospital. BMJ 338, b364.
32. Laarman, A., Milder, F., van Strijp, J. and Rooijakkers, S.2010) Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications. J. Mol. Med. 88, 115-120.
33. Lachmann, P.J., Pangburn, M.K., and Oldroyd, R.G.1982) Breakdown of C3 after complement activation. Identification of a new fragment, C3g, using monoclonal antibodies. J. Exp. Med. 156, 205-216.
34. Lambris, J.D.1988) The multifunctional role of C3, the third component of complement. Immunol. Today 9, 387-393.
35. Lambris, J.D., Ganu, V.S., Hirani, S., and Muller-Eberhard, H.J.1985) Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement. Proc. Natl. Acad. Sci. U.S.A. 82, 4235-4239.
36. Lambris, J.D., Ricklin, D. and Geisbrecht, B.V.2008) Complement evasion by human pathogens. Nat. Rev. Microbiol. 6, 132-142.
37. Lee, L.Y.L., Hook, M., Haviland, D., Wetsel, R.A., Yonter, E.O., Syribeys, P., Vernachio, J. and Brown, E.L.2004a) Inhibition of complement activation by a secreted Staphylococcus aureus protein. J. Infect. Dis. 190, 571-579.
38. Lee, L.Y.L., Liang, X., Hook, M. and Brown, E.L.2004b) Identification and characterization of the C3 binding domain of the Staphylococcus aureus extracellular fibrinogen-binding protein (Efb).J. Biol. Chem. 279, 50710-50716.
39. Mamo, W., Boden, M., and Flock, J.-I.1994) Vaccination with Staphylococcus aureus fibrinogenbinding proteins (FgBPs) reduces colonisation of S. aureus in a mouse mastitis model. FEMS Immunol. Med. Microbiol. 10, 47-53.
40. Morgan, H.P., Schmidt, C.Q., Guariento, M., Blaum, B.S., Gillsepie, D., Herbert, A.P., Kavanagh, D., Mertens, H.D., Svergun, D.I., Johansson, C.M., Uhrin, D., Barlow, P.N., and Hannan, J.P.2011) Structural basis for engagement by complement factor H of C3b on a self surface. Nat. Struct. Mol. Biol. 18, 463-470.
41. Nilsson, B., Svensson, K.E., Borwell, P., and Nilsson, U.R.1987) Production of mouse monoclonal antibodies that detect distinct neoantigenic epitopes on bound C3b and iC3b but not on the corresponding soluble fragments. Mol. Immunol. 24, 487-494.
42. Nilsson, U.R., and Nilsson, B.1982) Analogous antigenic alterations elicited in C3 by physiologic binding and by denaturation in the presence of sodium dodecylsulfate. J. Immunol. 129, 2594-2597.
43. Nishida, N., Walz, T. and Springer, T.A.2006) Structural transitions of complement component C3 and its activation products. Proc. Nat. Acad. Sci. U.S.A. 103, 19737-19742.
44. Palma, M., Nozohoor, S., Schennings, T., Heimdahl, A., and Flock, J.-I.1996) Lack of the extracellular 19-kilodalton fibrinogen-binding protein from Staphylococcus aureus decreases virulence in experimental wound infection. Infect. Immun. 64, 5284-5289.
45. Palma, M., Shannon, O., Quezada, H.C., Berg, A., and Flock, J.-I.2001) Extracellular fibrinogenbinding protein, Efb, from Staphylococcus aureus blocks platelet aggregation due to its binding the alpha-chain. J. Biol. Chem. 276, 31691-31697.
46. Palma, M., Wade, D., Flock, M., and Flock, J.-I.1998) Multiple binding sites in the interaction between an extracellular fibrinogen-binding protein from Staphylococcus aureus and fibrinogen. J. Biol. Chem. 273, 13177-13181.
47. Pangburn, M.K. and Muller-Eberhard, H.J.1986) The C3 convertase of the alternative pathway of human complement. Enzymic properties of the biomolecular proteinase. Biochem. J. 235, 723-730.
48. Ponnuraj, K., Xu, Y., Macon, K., Moore, D., Volanakis, J.E. and Narayana, S.V.2004) Structural analysis of engineered Bb fragment of complement factor B: insights into the activation mechanism of the alternative pathway C3-convertase. Mol. Cell 14, 17-28.
49. Ricklin, D., Hajishengallis, G., Yang, K. and Lambris, J.D.2010) Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11, 785-797.
50. Ricklin, D. and Lambris, J.D.2007) Complement-targeted therapeutics. Nat. Biotechnol. 25, 1265-1275.
51. Ricklin, D., Ricklin-Lichtsteiner, S.K., Markiewski, M.M., Geisbrecht, B.V. and Lambris, J.D (2008) Cutting edge: members of the Staphylococcus aureus extracellular fibrinogen-binding protein family inhibit the interaction of C3d with complement receptor 2. J. Immunol. 181, 7463-7467.
52. Ricklin, D., Tzekou, A., Garcia, B.L., Hammel, M., McWhorter, W.J., Sfyroera, G., Wu, Y.-Q., Holers, V.M., Herbert, A.P., Barlow, P.N., Geisbrecht, B.V. and Lambris, J.D.2009) A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family. J. Immunol. 183, 2565-2574.
53. Rooijakkers, S.H., Ruyken, M., Roos, A., Daha, M.R., Presanis, J.S., Sim, R.B., van Wamel, W.J., van Kessel, K.P. and van Strijp, J.A.2005) Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat. Immunol. 6, 920-927.
54. Rooijakkers, S.H., Wu, J., Ruyken, M., van Domselaar, R., Planken, K.L., Tzekou, A., Ricklin, D., Lambris, J.D., Janssen, B.J., van Strijp, J.A. and Gros, P.2009) Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat. Immunol. 10, 721-727.
55. Rooijakkers, S.H.M., Milder, F.J., Bardoel, B.W., Ruyken, M., van Strijp, J.A.G. and Gros, P.2007) Staphylococcal complement inhibitor: structure and active sites. J. Immunol. 179, 2989-2998.
56. Schuster, M.C., Ricklin, D., Papp, K., Molnar, K.S., Coales, S.J., Hamuro, Y., Sfyroera, G., Chen, H., Winters, M.S. and Lambris, J.D.2008) Dynamic structural changes during complement C3 activation analyzed by Hydrogen/Deuterium exchange mass spectrometry. Mol. Immunol. 45, 3142-3151.
57. Serruto, D., Rappuoli, R., Scarselli, M., Gros, P. and van Strijp, J.A.2010) Molecular mechanisms of complement evasion: learning from staphylococci and meningococci. Nat. Rev. Microbiol.8, 393-399.
58. Tamerius, J.D., Pangburn, M.K., and Muller-Eberhard, H.J.1985) Detection of a neoantigen on human C3bi and C3d by monoclonal antibody. J. Immunol. 135, 2015-2019.
59. Tsai, C.J., Del Sol, A. and Nussinov, R.2009) Protein allostery, signal transmission, and dynamics: a classification scheme of allosteric mechanisms. Mol. Biosyst. 5, 207-216.
60. Wiesmann, C., Katschke, K.J., Yin, J., Helmy, K.Y., Steffek, M., Fairbrother, W.J., McCallum, S.A., Embuscado, L., DeForge, L., Hass, P.E. and van Lookeren Campagne, M.2006) Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature 444, 217-220.
61. Wu, J., Wu, Y.Q., Ricklin, D., Janssen, B.J., Lambris, J.D. and Gros, P.2009) Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat. Immunol. 10, 728-733.
62. Zipfel, P.F. and Skerka, C.2009) Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 9, 729-740.